Clinical Trials Are at The Forefront of Cancer Research and Treatment – The US Oncology Network
The US Oncology Network shared a post on LinkedIn:
“Our work with the Sarah Cannon Research Institute (SCRI) has shown that clinical trials are at the forefront of cancer research and treatment. This is especially true when it comes to rare cancers, which make up fewer than 150 cases per million people every year.
As Vivek Subbiah of SCRI Oncology Partners notes in the American Society of Clinical Oncology (ASCO) article ‘Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras,’ organizing clinical trials for rare cancers can be challenging because these cancers involve limited patient populations, geographical dispersion, and economic limitations.
However, there is a bright side: new tech like next-generation sequencing and precision medicine may be the key.”
Proceed to the video attached to the post.
Title: Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras
Authors: Vivek Subbiah, Megan Othus, Jim Palma, Branko Cuglievan, Razelle Kurzrock
You can read the Full Article on American Society of Clinical Oncology Educational Book
More posts featuring The US Oncology Network
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023